Table 3. IOS inhaled therapy response studies in Adult Asthma.

Study	Effect Size Δ R5-R20 (kPa/L/s)	Standard Deviation of R5-R20 (where reported)
Hoshino M; Allergolint 2010 ciclesonide 200 microg once daily or fluticasone propionate 100 microg twice daily for 8 weeks. [N=36]; GINA Step 2 @ baseline	0.02	0.06-0.07
Hozawa S et al PulmPharmacolTher 2011 twice daily BUD/FM 320/9 μg or FP/SM 250/50 μg, and treatment efficacy was compared after 4 weeks [n=40]	0.04	0.02-0.03
Hozawa S et al PulmPharmacolTher 2014 Two inhalations twice-daily BUD/FM 160/4.5 μg plus as-needed BUD/FM (SMART group, n = 15) or one inhalation twice-daily FP/SM 250/50 μg plus as-needed procaterol (FP/SM group, n = 15) for 8 weeks.	0.04	0.02-0.03
Manoharan A et al, JACI 2016. 4 weeks of open label crossover study salmeterol 50 mcg DPI bid vs extra fine 12mcg HFA-formoterol bid.	% change reported	SD of % change reported
Hozawa S, PilmPharmacolTher 2016 4 Weeks, BUD/FM 160/4.5 +PRN (SMART) or FF/Vilanterol 100/25 + PRN Procaterol in poorly controlled on moderate dose ICS and FENO high asthma. Randomised open label	0.03	0.02-0.03